ClinicalTrials.gg
CompletedNCT04803305Updated Jan 12, 2024Results posted

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

A Phase 1 interventional study of PF-06946860 and Placebo for PF-06946860 in Non-small Cell Lung Cancer, Pancreatic Cancer and Colorectal Cancer, sponsored by Pfizer. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
117th of 136
18 · median 79
Started
2021
with 11 others
Phase 1
56 of 158
6 open now
Registered
112th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 117th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2021, is one of 56 in phase 1, and was the 112th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under the skin) doses.

Read the detailed description

A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin (subcutaneously).

During the initial 6-week treatment period (Part A), a total of 2 doses of study drug or placebo will be administered 3 weeks apart. Each dose contains two injections. Part B is an optional 18-week open-label treatment period where up to 7 doses of study drug may be administered. Part B does not include placebo.

Assessments include:

  • Measure the impact of the study drug on appetite, fatigue, and pain questionnaires
  • Body weight measurements
  • Blood samples to evaluate safety and additional endpoints including the amount of the study drug in the blood and the effects of the study drug on levels of a specific cytokine.
03

Conditions studied

  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Loss of Appetite
  • Fatigue
  • Cachexia
  • Anorexia

Keywords

  • cancer, anorexia, cachexia, weight loss, loss of appetite, fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced.
  • Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite 7-day recall scale
  • Meets any of the following criteria at Randomization:

    • Not currently receiving antineoplastic therapy
    • On standard of care systemic antineoplastic therapy or treatment without curative intent
  • Signed .

Key Exclusion Criteria:

  • Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
  • Current active reversible causes of decreased food intake.
  • Current, severe gastrointestinal disease
  • Participants with known symptomatic requiring .
  • Active uncontrolled bacterial, fungal, or viral infection, including , , or participants with known AIDS-related illness
  • inadequate renal or liver function.
  • Women who are pregnant or breast-feeding
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 Treatment

    subcutaneous injection

    Drug: PF-06946860

  • Placebo comparator
    Double-Blind Placebo Treatment followed by Open-Label PF-06946860 Treatment

    subcutaneous injection

    Drug: PF-06946860 · Drug: Placebo for PF-06946860

Interventions

  • subcutaneous injection

  • DrugPlacebo for PF-06946860

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A

    The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A

    The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score were summarized descriptively by treatment group and timepoint.

    Time frame: Baseline, Weeks 1, 2, 3, 5 and 6

  2. Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A

    The Cancer-Related Cachexia Symptom Assessment-Fatigue was a self-reported questionnaire that measured the severity of fatigue. The measure consisted of 1 question that asked study participants to rate their fatigue over the past 7 days from 0-"no fatigue" to 10-"worst possible fatigue", where higher score indicated worse fatigue. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Fatigue score were summarized descriptively by treatment group and timepoint.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5 and 6

  3. Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are events between first dose of study drug and up to discharge from study that are absent before treatment or that worsen relative to pretreatment state. An SAE is any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.

    Time frame: Day 1 through Week 6 (for a period of 6 weeks)

  4. Number of Participants With Laboratory Test Abnormalities in Part A

    Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, erythrocytes mean corpuscular volume, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular hemoglobin concentration, platelets, leukocytes, lymphocytes, basophils, eosinophils and monocytes), chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate and glucose) and urine (pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes \[/high power field (HPF)\], urine leukocytes \[/HPF\] and hyaline casts \[/low power field (LPF)\]).

    Time frame: Days 1, 22 and 43

07

Results

Posted Jan 12, 2024

Participant flow

Part A: 6-week Double-blind Treatment
Participant flow — Part A: 6-week Double-blind Treatment
MilestonePlacebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W
Started612
Completed59
Not completed13
Withdrew: Death02
Withdrew: Withdrawal by subject01
Withdrew: Physician decision10
Part B: OLT Period up to 18 Weeks
Participant flow — Part B: OLT Period up to 18 Weeks
MilestonePlacebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W
Started59
Completed25
Not completed34
Withdrew: Other01
Withdrew: Withdrawal by subject10
Withdrew: Physician decision01
Withdrew: Death12
Withdrew: Adverse event10

Outcome measures

PrimaryChange From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A

The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A
Units on a ScalePlaceboPF-06946860 200mg Q3W
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A2.45 (1.01 to 3.88)1.84 (0.79 to 2.90)
Statistical analysis
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): -0.60 · 90% CI -2.38 to 1.18Week 4
SecondaryChange From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A

The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score were summarized descriptively by treatment group and timepoint.

Time frame:
Baseline, Weeks 1, 2, 3, 5 and 6
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A
Units on a ScalePlaceboPF-06946860 200mg Q3W
Week 10.99 (-0.66 to 2.64)2.19 (1.17 to 3.20)
Week 21.11 (-0.03 to 2.25)2.21 (1.45 to 2.98)
Week 31.27 (-0.35 to 2.89)2.30 (1.20 to 3.41)
Week 51.95 (0.27 to 3.63)1.95 (0.82 to 3.08)
Week 62.41 (0.49 to 4.33)1.61 (0.32 to 2.90)
Statistical analysis
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 1.20 · 90% CI -0.75 to 3.15Week 1
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 1.10 · 90% CI -0.28 to 2.49Week 2
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 1.03 · 90% CI -0.93 to 2.99Week 3
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 0.00 · 90% CI -2.02 to 2.02Week 5
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): -0.80 · 90% CI -3.11 to 1.51Week 6
SecondaryChange From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A

The Cancer-Related Cachexia Symptom Assessment-Fatigue was a self-reported questionnaire that measured the severity of fatigue. The measure consisted of 1 question that asked study participants to rate their fatigue over the past 7 days from 0-"no fatigue" to 10-"worst possible fatigue", where higher score indicated worse fatigue. In this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Fatigue score were summarized descriptively by treatment group and timepoint.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5 and 6
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A
Units on a ScalePlaceboPF-06946860 200mg Q3W
Week 11.84 (-1.47 to 5.16)1.52 (-0.57 to 3.60)
Week 20.04 (-2.71 to 2.80)-2.12 (-3.91 to -0.34)
Week 3-1.21 (-2.33 to -0.09)-0.49 (-1.23 to 0.25)
Week 4-1.00 (-2.40 to 0.40)-0.55 (-1.57 to 0.48)
Week 5-0.92 (-2.47 to 0.63)-0.24 (-1.31 to 0.82)
Week 6-1.13 (-2.40 to 0.15)0.74 (-0.09 to 1.57)
Statistical analysis
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): -0.32 · 90% CI -4.18 to 3.53Week 1
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): -2.16 · 90% CI -5.49 to 1.16Week 2
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 0.72 · 90% CI -0.62 to 2.06Week 3
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 0.45 · 90% CI -1.29 to 2.20Week 4
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 0.68 · 90% CI -1.21 to 2.57Week 5
  • Placebo vs PF-06946860 200mg Q3W · Mean difference (final values): 1.86 · 90% CI 0.34 to 3.39Week 6
SecondaryNumber of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs are events between first dose of study drug and up to discharge from study that are absent before treatment or that worsen relative to pretreatment state. An SAE is any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.

Time frame:
Day 1 through Week 6 (for a period of 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A
ParticipantsPlaceboPF-06946860 200mg Q3W
Participants With All-Causality TEAEs47
Participants With All-Causality SAEs13
SecondaryNumber of Participants With Laboratory Test Abnormalities in Part A

Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, erythrocytes mean corpuscular volume, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular hemoglobin concentration, platelets, leukocytes, lymphocytes, basophils, eosinophils and monocytes), chemistry (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate and glucose) and urine (pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes \[/high power field (HPF)\], urine leukocytes \[/HPF\] and hyaline casts \[/low power field (LPF)\]).

Time frame:
Days 1, 22 and 43
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities in Part A
ParticipantsPlaceboPF- 06946860 200mg Q3W
Hemoglobin <0.8 x lower limit of normal (LLN)24
Hematocrit <0.8 x LLN23
Erythrocytes <0.8 x LLN14
Erythrocytes Mean Corpuscular Volume <0.9 x LLN00
Erythrocytes Mean Corpuscular Volume >1.1 x upper limit of normal (ULN)01
Erythrocytes Mean Corpuscular Hemoglobin <0.9 x LLN01
Erythrocytes Mean Corpuscular Hemoglobin >1.1 x ULN00
Erythrocytes Mean Corpuscular Hemoglobin Concentration <0.9 x LLN00
Erythrocytes Mean Corpuscular Hemoglobin Concentration >1.1 x ULN00
Platelets <0.5 x LLN00
Platelets >1.75 x ULN01
Leukocytes <0.6 x LLN10
Leukocytes >1.5 x ULN00
Lymphocytes <0.8 x LLN26
Lymphocytes >1.2 x ULN00
Basophils >1.2 x ULN01
Eosinophils >1.2 x ULN00
Monocytes >1.2 x ULN01
Bilirubin >1.5 x ULN00
Aspartate Aminotransferase >3.0 x ULN00
Alanine Aminotransferase >3.0 x ULN00
Alkaline Phosphatase >3.0 x ULN02
Protein <0.8 x LLN10
Protein >1.2 x ULN00
Albumin <0.8 x LLN00
Albumin >1.2 x ULN00
Blood Urea Nitrogen >1.3 x ULN00
Creatinine >1.3 x ULN01
Urate >1.2 x ULN00
Sodium <0.95 x LLN00
Sodium >1.05 x ULN00
Potassium <0.9 x LLN00
Potassium >1.1 x ULN00
Chloride <0.9 x LLN00
Chloride >1.1 x ULN00
Calcium <0.9 x LLN00
Calcium >1.1 x ULN00
Bicarbonate <0.9 x LLN11
Bicarbonate >1.1 x ULN00
Glucose <0.6 x LLN00
Glucose >1.5 x ULN12
pH <4.500
pH >800
Urine Glucose >=101
Ketones >=100
Urine Protein >=120
Urine Hemoglobin >=102
Urobilinogen >=100
Urine Bilirubin >=100
Nitrite >=101
Leukocyte Esterase >=112
Urine Erythrocytes (/HPF) >=2001
Urine Leukocytes (/HPF) >=2001
Hyaline Casts (/LPF) >102

Adverse events

Collected over Part A: Day 1 through Week 6 Part A + Part B: up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/6 (16.7%)1/6 (16.7%)4/6 (66.7%)
PF-06946860 200mg Q3W2/12 (16.7%)3/12 (25%)4/12 (33.3%)
Placebo -> OL PF-06946860 200mg Q3W2/6 (33.3%)2/6 (33.3%)6/6 (100%)
PF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W4/12 (33.3%)5/12 (41.7%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-06946860 200mg Q3WPlacebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W
Cardiac arrestCardiac disorders1/60/121/60/12
Disease progressionGeneral disorders0/60/121/62/12
HypokalaemiaMetabolism and nutrition disorders1/60/121/60/12
Acute myocardial infarctionCardiac disorders0/61/120/61/12
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/61/120/61/12
Respiratory failureRespiratory, thoracic and mediastinal disorders0/61/120/61/12
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboPF-06946860 200mg Q3WPlacebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3W
ConstipationGastrointestinal disorders0/60/122/60/12
FallInjury, poisoning and procedural complications1/60/122/60/12
Urinary tract infectionInfections and infestations1/63/121/63/12
Ocular hyperaemiaEye disorders0/60/121/60/12
Abdominal pain lowerGastrointestinal disorders0/60/121/60/12
NauseaGastrointestinal disorders0/61/121/62/12
VomitingGastrointestinal disorders0/61/120/62/12
FatigueGeneral disorders0/60/121/61/12
Gait disturbanceGeneral disorders0/60/121/60/12
OedemaGeneral disorders0/60/121/60/12

Baseline characteristics

The baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Placebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3WTotal
Mean68.0 ± 7.9574.0 ± 9.1272.0 ± 8.99
Age, Customized
Age, Customized(Participants)Placebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3WTotal
<18000
18-44000
45-64224
>=6541014
Sex: Female, Male
Sex: Female, Male(Participants)Placebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3WTotal
Female257
Male4711
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3WTotal
Hispanic or Latino011
Not Hispanic or Latino51116
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo -> OL PF-06946860 200mg Q3WPF-06946860 200mg Q3W -> OL PF-06946860 200mg Q3WTotal
White31114
Black or African American303
Asian011
08

Study locations

33 sites
  • CARTI Cancer Center
    Little Rock, Arkansas 72205, United States
  • Tower Hematology Oncology Medical Group (THO)
    Beverly Hills, California 90211, United States
  • Ventura County Hematology- Oncology Specialists
    Camarillo, California 93010, United States
  • Cedars- Sinai Medical Center
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
  • Ventura County Hematology-Oncology Specialists
    Ventura, California 93003, United States
  • Lutheran Medical Center
    Wheat Ridge, Colorado 80033, United States
  • Fort Wayne Medical Oncology and Hematology, Inc.
    Fort Wayne, Indiana 46804, United States
  • Bozeman Health Cancer Center
    Bozeman, Montana 59715, United States
  • Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research
    Bozeman, Montana 59715, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • US Oncology Investigational Product Center (IPC)
    Irving, Texas 75063, United States
  • Texas Oncology - Longview Cancer Center
    Longview, Texas 75601, United States
  • Texas Oncology-Paris
    Paris, Texas 75460, United States
  • Texas Oncology- Tyler
    Tyler, Texas 75702, United States
  • Cancer Center IDS Pharmacy
    Charlottesville, Virginia 22903, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22903, United States
  • UVA Health System; Attention: GI Team
    Charlottesville, Virginia 22903, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • MultiCare Regional Cancer Center - Auburn
    Auburn, Washington 98001, United States
  • MultiCare Regional Cancer Center - Gig Harbor Medical Park
    Gig Harbor, Washington 98335, United States
  • Moses Lake Clinic
    Moses Lake, Washington 98837, United States
  • MultiCare Regional Cancer Center - Puyallup
    Puyallup, Washington 98372, United States
  • Medical Oncology Associates, PS (dba Summit Cancer Centers)
    Spokane Valley, Washington 99216, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • MultiCare Regional Cancer Center - Tacoma
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital
    Wenatchee, Washington 98801, United States
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Apr 2022, 11 months.

Results were first posted in Jan 2024, 1 year 8 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 11 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 17, 2021
StartActual
May 11, 2021
Primary completionActual
Apr 14, 2022
CompletionActual
Aug 9, 2022
Results first posted
Jan 12, 2024
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04803305
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
May 11, 2021
Primary completion
Apr 14, 2022
Completion
Aug 9, 2022
Results posted
Jan 12, 2024
Last update
Jan 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponsegromab

Start the discussion